A human patient-derived organoid biobank to model tumor heterogeneity and therapeutic vulnerability for oral squamous cell carcinoma - PubMed
3 days ago
- #chemoresistance
- #OSCC
- #patient-derived organoids
- A living biobank of 46 OSCC patient-derived organoids (PDOs) was established to model tumor heterogeneity and therapeutic vulnerability.
- PDOs faithfully recapitulate histopathological, genetic, and molecular features of parental tumors, enabling disease modeling, genetic manipulation, and drug screening.
- CDCP1 was identified as a mediator of cisplatin resistance via Wnt/β-catenin signaling-driven stemness.
- A pH-sensitive nanoparticle delivering siCDCP1 was developed, effectively restoring chemosensitivity and impairing tumor growth in cisplatin-resistant PDX models.
- PDOs serve as robust preclinical models for mechanistic explorations and therapeutics development in OSCC.